Estimating tissue iron burden: Current status and future prospects

British Journal of Haematology

Volumn 170, Issue 1, 2015, Pages 15-28

  Wood, John C ^a  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

Imaging; Iron; Iron overload; Sickle cell anaemia; Thalassaemia

Indexed keywords

BIOLOGICAL MARKER; FERRITIN; IRON;

ARTICLE; BIOAVAILABILITY; BIOPSY; CARDIOVASCULAR RISK; COMPUTER ASSISTED TOMOGRAPHY; FERRITIN BLOOD LEVEL; HEART; HUMAN; HYPOPHYSIS; IRON INTAKE; IRON OVERLOAD; LIVER LEVEL; MEASUREMENT ACCURACY; MEDICAL DEVICE; METABOLIC REGULATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS; PRIORITY JOURNAL; PROTOCOL COMPLIANCE; SUSCEPTOMETER; TISSUE LEVEL; METABOLISM; SICKLE CELL ANEMIA; THALASSEMIA; TISSUE DISTRIBUTION;

ANEMIA, SICKLE CELL; HUMANS; IRON; IRON OVERLOAD; THALASSEMIA; TISSUE DISTRIBUTION;

EID: 84931578381     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13374     Document Type: Article

References (106)

1. Adams, P.C. & Barton, J.C. (2007) Haemochromatosis. Lancet, 370, 1855-1860.
2. Anderson, L.J., Holden, S., Davis, B., Prescott, E., Charrier, C.C., Bunce, N.H., Firmin, D.N., Wonke, B., Porter, J., Walker, J.M. & Pennell, D.J. (2001) Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. European Heart Journal, 22, 2171-2179.
3. Anderson, L.J., Westwood, M.A., Holden, S., Davis, B., Prescott, E., Wonke, B., Porter, J.B., Malcolm Walker, J. & Pennell, D.J. (2004) Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. British Journal of Haematology, 127, 348-355.
4. Angelucci, E., Baronciani, D., Lucarelli, G., Baldassarri, M., Galimberti, M., Giardini, C., Martinelli, F., Polchi, P., Polizzi, V. & Ripalti, M. (1995) Needle liver biopsy in thalassaemia: analyses of diagnostic accuracy and safety in 1184 consecutive biopsies. British Journal of Haematology, 89, 757-761.
5. Angelucci, E., Brittenham, G.M., McLaren, C.E., Ripalti, M., Baronciani, D., Giardini, C., Galimberti, M., Polchi, P. & Lucarelli, G. (2000) Hepatic iron concentration and total body iron stores in thalassemia major. New England Journal of Medicine, 343, 327-331.
6. Argyropoulou, M.I., Metafratzi, Z., Kiortsis, D.N., Bitsis, S., Tsatsoulis, A. & Efremidis, S. (2000) T2 relaxation rate as an index of pituitary iron overload in patients with beta-thalassemia major. American Journal of Roentgenology, 175, 1567-1569.
7. Argyropoulou, M.I., Kiortsis, D.N., Metafratzi, Z., Bitsis, S., Tsatoulis, A. & Efremidis, S.C. (2001) Pituitary gland height evaluated by MR in patients with beta-thalassemia major: a marker of pituitary gland function. Neuroradiology, 43, 1056-1058.
8. Barry, M., Flynn, D., Letsky, E.A. & Risdon, R.A. (1974) Long-term chelation therapy in thalassemia major: effect on LIC, liver histology, and clinical progress. British Medical Journal, 2, 16-20.
9. Barton, J.C., Barton, J.C., Acton, R.T., So, J., Chan, S. & Adams, P.C. (2012) Increased risk of death from iron overload among 422 treated probands with HFE hemochromatosis and serum levels of ferritin greater than 1000 μg/L at diagnosis. Clinical Gastroenterology and Hepatology, 10, 412-416.
10. Berdoukas, V., Nord, A., Carson, S., Puliyel, M., Hofstra, T., Wood, J. & Coates, T.D. (2013) Tissue iron evaluation in chronically transfused children shows significant levels of iron loading at a very young age. American Journal of Hematology, 88, E283-E285.
11. Bergman, R.N., Finegood, D.T. & Kahn, S.E. (2002) The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes. European Journal of Clinical Investigation, 32, 35-45.
12. Borgna-Pignatti, C., Rugolotto, S., De Stefano, P., Zhao, H., Cappellini, M.D., Del Vecchio, G.C., Romeo, M.A., Forni, G.L., Gamberini, M.R., Ghilardi, R., Piga, A. & Cnaan, A. (2004) Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica, 89, 1187-1193.
13. Breuer, W., Ronson, A., Slotki, I.N., Abramov, A., Hershko, C. & Cabantchik, Z.I. (2000) The assessment of serum nontransferrin-bound iron in chelation therapy and iron supplementation. Blood, 95, 2975-2982.
14. Brewer, C., Otto-Duessel, M., Lykkesfeldt, J., Nick, H. & Wood, J.C. (2012) Ascorbate status modulates reticuloendothelial iron stores and response to deferasirox iron chelation in ascorbate-deficient rats. Experimental Hematology, 40, 820-827.
15. Brewer, C.J., Wood, R.I. & Wood, J.C. (2014) mRNA regulation of cardiac iron transporters and ferritin subunits in a mouse model of iron overload. Experimental Hematology, 42, 1059-67.
16. Brissot, P., Bourel, M., Herry, D., Verger, J.P., Messner, M., Beaumont, C., Regnouard, F., Ferrand, B. & Simon, M. (1981) Assessment of liver iron content in 271 patients: a reevaluation of direct and indirect methods. Gastroenterology, 80, 557-565.
17. Brittenham, G.M., Farrell, D.E., Harris, J.W., Feldman, E.S., Danish, E.H., Muir, W.A., Tripp, J.H. & Bellon, E.M. (1982) Magnetic-susceptibility measurement of human iron stores. New England Journal of Medicine, 307, 1671-1675.
18. Brittenham, G.M., Cohen, A.R., McLaren, C.E., Martin, M.B., Griffith, P.M., Nienhuis, A.W., Young, N.S., Allen, C.J., Farrell, D.E. & Harris, J.W. (1993) Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. American Journal of Hematology, 42, 81-85.
19. Brittenham, G.M., Griffith, P.M., Nienhuis, A.W., McLaren, C.E., Young, N.S., Tucker, E.E., Allen, C.J., Farrell, D.E. & Harris, J.W. (1994) Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. New England Journal of Medicine, 331, 567-573.
20. Butensky, E., Fischer, R., Hudes, M., Schumacher, L., Williams, R., Moyer, T.P., Vichinsky, E. & Harmatz, P. (2005) Variability in hepatic iron concentration in percutaneous needle biopsy specimens from patients with transfusional hemosiderosis. American Journal of Clinical Pathology, 123, 146-152.
21. Cabantchik, Z.I. (2014) Labile iron in cells and body fluids: physiology, pathology, and pharmacology. Fronteirs in Pharmacology, 5, 45.
22. Carpenter, J.P., He, T., Kirk, P., Roughton, M., Anderson, L.J., de Noronha, S.V., Sheppard, M.N., Porter, J.B., Walker, J.M., Wood, J.C., Galanello, R., Forni, G., Catani, G., Matta, G., Fucharoen, S., Fleming, A., House, M.J., Black, G., Firmin, D.N., St Pierre, T.G. & Pennell, D.J. (2011) On T2* magnetic resonance and cardiac iron. Circulation, 123, 1519-1528.
23. Chapman, R.W., Hussain, M.A., Gorman, A., Laulicht, M., Politis, D., Flynn, D.M., Sherlock, S. & Hoffbrand, A.V. (1982) Effect of ascorbic acid deficiency on serum ferritin concentration in patients with beta-thalassaemia major and iron overload. Journal of Clinical Pathology, 35, 487-491.
24. Claster, S., Wood, J.C., Noetzli, L., Carson, S.M., Hofstra, T.C., Khanna, R. & Coates, T.D. (2009) Nutritional deficiencies in iron overloaded patients with hemoglobinopathies. American Journal of Hematology, 84, 344-348.
25. Cohen, A.R., Glimm, E. & Porter, J.B. (2008) Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major. Blood, 111, 583-587.
26. Corradini, E., Meynard, D., Wu, Q., Chen, S., Ventura, P., Pietrangelo, A. & Babitt, J.L. (2011) Serum and liver iron differently regulate the bone morphogenetic protein 6 (BMP6)-SMAD signaling pathway in mice. Hepatology, 54, 273-284.
27. Danjou, F., Cabantchik, Z.I., Origa, R., Moi, P., Marcias, M., Barella, S., Defraia, E., Dessi, C., Foschini, M.L., Giagu, N., Leoni, G.B., Morittu, M. & Galanello, R. (2014) A decisional algorithm to start iron chelation in patients with beta thalassemia. Haematologica, 99, e38-e40.
28. Davis, B.A. & Porter, J.B. (2000) Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood, 95, 1229-1236.
29. Evans, R.W., Rafique, R., Zarea, A., Rapisarda, C., Cammack, R., Evans, P.J., Porter, J.B. & Hider, R.C. (2008) Nature of non-transferrin-bound iron: studies on iron citrate complexes and thalassemic sera. Journal of Biological Inorganic Chemistry, 13, 57-74.
30. Farmaki, K., Tzoumari, I., Pappa, C., Chouliaras, G. & Berdoukas, V. (2010) Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. British Journal of Hematology, 148, 466-475.
31. Feng, Y., He, T., Carpenter, J.P., Jabbour, A., Alam, M.H., Gatehouse, P.D., Greiser, A., Messroghli, D., Firmin, D.N. & Pennell, D.J. (2013) In vivo comparison of myocardial T1 with T2 and T2* in thalassaemia major. Journal of Magnetic Resonance Imaging, 38, 588-593.
32. Fischer, R., Harmatz, P. & Nielsen, P. (2006) Does liver biopsy overestimate liver iron concentration? Blood, 108, 778.
33. Gandon, Y., Guyader, D., Heautot, J.F., Reda, M.I., Yaouanq, J., Buhe, T., Brissot, P., Carsin, M. & Deugnier, Y. (1994) Hemochromatosis: diagnosis and quantification of liver iron with gradient-echo MR imaging. Radiology, 193, 533-538.
34. Ganz, T. (2007) Molecular control of iron transport. Journal of the American Society of Nephrology, 18, 394-400.
35. Garbowski, M.W., Carpenter, J.P., Smith, G., Roughton, M., Alam, M.H., He, T., Pennell, D.J. & Porter, J.B. (2014) Biopsy-based calibration of T2* magnetic resonance for estimation of liver iron concentration and comparison with R2 Ferriscan. Journal of Cardiovascular Magnetic Resonance, 16, 40.
36. Ghugre, N.R. & Wood, J.C. (2011) Relaxivity-iron calibration in hepatic iron overload: probing underlying biophysical mechanisms using a Monte Carlo model. Magnetic Resonance in Medicine, 65, 837-847.
37. Ghugre, N.R., Enriquez, C.M., Gonzalez, I., Nelson, Jr, M.D., Coates, T.D. & Wood, J.C. (2006) MRI detects myocardial iron in the human heart. Magnetic Resonance in Medicine, 56, 681-686.
38. Gianesin, B., Zefiro, D., Musso, M., Rosa, A., Bruzzone, C., Balocco, M., Carrara, P., Bacigalupo, L., Banderali, S., Rollandi, G.A., Gambaro, M., Marinelli, M. & Forni, G.L. (2012) Measurement of liver iron overload: noninvasive calibration of MRI-R2* by magnetic iron detector susceptometer. Magnetic Resonance in Medicine, 67, 1782-1786.
39. Goldberg, H.I., Cann, C.E., Moss, A.A., Ohto, M., Brito, A. & Federle, M. (1982) Noninvasive quantitation of liver iron in dogs with hemochromatosis using dual-energy CT scanning. Investigative Radiology, 17, 375-380.
40. Gosriwatana, I., Loreal, O., Lu, S., Brissot, P., Porter, J. & Hider, R.C. (1999) Quantification of non-transferrin-bound iron in the presence of unsaturated transferrin. Analytic Biochemistry, 273, 212-220.
41. Hankins, J.S., McCarville, M.B., Loeffler, R.B., Smeltzer, M.P., Onciu, M., Hoffer, F.A., Li, C.S., Wang, W.C., Ware, R.E. & Hillenbrand, C.M. (2009) R2* magnetic resonance imaging of the liver in patients with iron overload. Blood, 113, 4853-4855.
42. He, T., Smith, G.C., Gatehouse, P.D., Mohiaddin, R.H., Firmin, D.N. & Pennell, D.J. (2009) On using T2 to assess extrinsic magnetic field inhomogeneity effects on T2* measurements in myocardial siderosis in thalassemia. Magnetic Resonance in Medicine, 61, 501-506.
43. Inati, A., Musallam, K.M., Wood, J.C. & Taher, A.T. (2010) Iron overload indices rise linearly with transfusion rate in patients with sickle cell disease. Blood, 115, 2980-2981; author reply 2981-2982.
44. Jacobs, E.M., Hendriks, J.C., van Tits, B.L., Evans, P.J., Breuer, W., Liu, D.Y., Jansen, E.H., Jauhiainen, K., Sturm, B., Porter, J.B., Scheiber-Mojdehkar, B., von Bonsdorff, L., Cabantchik, Z.I., Hider, R.C. & Swinkels, D.W. (2005) Results of an international round robin for the quantification of serum non-transferrin-bound iron: need for defining standardization and a clinically relevant isoform. Analytic Biochemistry, 341, 241-250.
45. Jensen, J.H. & Chandra, R. (2002) Theory of nonexponential NMR signal decay in liver with iron overload or superparamagnetic iron oxide particles. Magnetic Resonance in Medicine, 47, 1131-1138.
46. Kattamis, A., Papassotiriou, I., Palaiologou, D., Apostolakou, F., Galani, A., Ladis, V., Sakellaropoulos, N. & Papanikolaou, G. (2006) The effects of erythropoetic activity and iron burden on hepcidin expression in patients with thalassemia major. Haematologica, 91, 809-812.
47. Kautz, L., Jung, G., Valore, E.V., Rivella, S., Nemeth, E. & Ganz, T. (2014) Identification of erythroferrone as an erythroid regulator of iron metabolism. Nature Genetics, 46, 678-684.
48. Kim, D., Jensen, J.H., Wu, E.X., Feng, L., Au, W.Y., Cheung, J.S., Ha, S.Y., Sheth, S.S. & Brittenham, G.M. (2011) Rapid monitoring of iron-chelating therapy in thalassemia major by a new cardiovascular MR measure: the reduced transverse relaxation rate. NMR in Biomedicine, 24, 771-777.
49. Kirk, P., Roughton, M., Porter, J.B., Walker, J.M., Tanner, M.A., Patel, J., Wu, D., Taylor, J., Westwood, M.A., Anderson, L.J. & Pennell, D.J. (2009) Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation, 120, 1961-1968.
50. Kountouras, D., Tsagarakis, N.J., Fatourou, E., Dalagiorgos, E., Chrysanthos, N., Berdoussi, H., Vgontza, N., Karagiorga, M., Lagiandreou, A., Kaligeros, K., Voskaridou, E., Roussou, P., Diamanti-Kandarakis, E. & Koskinas, J. (2013) Liver disease in adult transfusion-dependent beta-thalassaemic patients: investigating the role of iron overload and chronic HCV infection. Liver International, 33, 420-427.
51. Kowdley, K.V., Belt, P., Wilson, L.A., Yeh, M.M., Neuschwander-Tetri, B.A., Chalasani, N., Sanyal, A.J. & Nelson, J.E. (2012) Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology, 55, 77-85.
52. Meloni, A., Rienhoff, Jr, H.Y., Jones, A., Pepe, A., Lombardi, M. & Wood, J.C. (2013) The use of appropriate calibration curves corrects for systematic differences in liver R2* values measured using different software packages. British Journal of Hematology, 161, 888-891.
53. Meloni, A., Puliyel, M., Pepe, A., Berdoukas, V., Coates, T.D. & Wood, J.C. (2014) Cardiac iron overload in sickle-cell disease. American Journal of Hematology, 89, 678-683.
54. Modell, B., Khan, M. & Darlison, M. (2000) Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet, 355, 2051-2052.
55. Morgan, E.H. & Walters, M.N. (1963) Iron storage in human disease: fractionation of hepatic and splenic iron into ferritin and haemosiderin with histochemical correlations. Journal of Clinical Pathology, 16, 101-107.
56. Musallam, K.M., Cappellini, M.D., Wood, J.C., Motta, I., Graziadei, G., Tamim, H. & Taher, A.T. (2011) Elevated liver iron concentration is a marker of increased morbidity in patients with beta thalassemia intermedia. Haematologica, 96, 1605-1612.
57. Nielsen, P., Engelhardt, R., Duerken, M., Janka, G.E. & Fischer, R. (2000) Using SQUID biomagnetic liver susceptometry in the treatment of thalassemia and other iron loading diseases. Transfusion Sciences, 23, 257-258.
58. Noetzli, L.J., Carson, S.M., Nord, A.S., Coates, T.D. & Wood, J.C. (2008) Longitudinal analysis of heart and liver iron in thalassemia major. Blood, 112, 2973-2978.
59. Noetzli, L.J., Papudesi, J., Coates, T.D. & Wood, J.C. (2009) Pancreatic iron loading predicts cardiac iron loading in thalassemia major. Blood, 114, 4021-4026.
60. Noetzli, L.J., Panigrahy, A., Mittelman, S.D., Hyderi, A., Dongelyan, A., Coates, T.D. & Wood, J.C. (2012a) Pituitary iron and volume predict hypogonadism in transfusional iron overload. American Journal of Hematology, 87, 167-171.
61. Noetzli, L.J., Mittelman, S.D., Watanabe, R.M., Coates, T.D. & Wood, J.C. (2012b) Pancreatic iron and glucose dysregulation in thalassemia major. American Journal of Hematology, 87, 155-160.
62. Noetzli, L.J., Panigrahy, A., Hyderi, A., Dongelyan, A., Coates, T.D. & Wood, J.C. (2012c) Pituitary iron and volume imaging in healthy controls. AJNR. American Journal of Neuroradiology, 33, 259-265.
63. Olivieri, N.F., Nathan, D.G., MacMillan, J.H., Wayne, A.S., Liu, P.P., McGee, A., Martin, M., Koren, G. & Cohen, A.R. (1994) Survival in medically treated patients with homozygous beta-thalassemia. New England Journal of Medicine, 331, 574-578.
64. 2+ channels in iron transport and iron-overload cardiomyopathy. Journal of Molecular Medicine, 84, 349-364.
65. Pennell, D.J., Berdoukas, V., Karagiorga, M., Ladis, V., Piga, A., Aessopos, A., Gotsis, E.D., Tanner, M.A., Smith, G.C., Westwood, M.A., Wonke, B. & Galanello, R. (2006) Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood, 107, 3738-3744.
66. Pennell, D.J., Porter, J.B., Cappellini, M.D., El-Beshlawy, A., Chan, L.L., Aydinok, Y., Elalfy, M.S., Sutcharitchan, P., Li, C.K., Ibrahim, H., Viprakasit, V., Kattamis, A., Smith, G., Habr, D., Domokos, G., Roubert, B. & Taher, A. (2010) Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood, 115, 2364-2371.
67. Pennell, D.J., Udelson, J.E., Arai, A.E., Bozkurt, B., Cohen, A.R., Galanello, R., Hoffman, T.M., Kiernan, M.S., Lerakis, S., Piga, A., Porter, J.B., Walker, J.M. & Wood, J. (2013) Cardiovascular function and treatment in beta-thalassemia major: a consensus statement from the American Heart Association. Circulation, 128, 281-308.
68. Pfeifer, C.D., Schoennagel, B.P., Grosse, R., Wang, Z.J., Graessner, J., Nielsen, P., Adam, G., Fischer, R. & Yamamura, J. (2014) Pancreatic iron and fat assessment by MRI-R2* in patients with iron overload diseases. Journal of Magnetic Resonance Imaging, doi:10.1002/jmri.24752 Epub ahead of print.
69. Piga, A., Longo, F., Duca, L., Roggero, S., Vinciguerra, T., Calabrese, R., Hershko, C. & Cappellini, M.D. (2009) High nontransferrin bound iron levels and heart disease in thalassemia major. American Journal of Hematology, 84, 29-33.
70. Pootrakul, P., Breuer, W., Sametband, M., Sirankapracha, P., Hershko, C. & Cabantchik, Z.I. (2004) Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with an oral chelator. Blood, 104, 1504-1510.
71. Porter, J.B. (2007) Concepts and goals in the management of transfusional iron overload. American Journal of Hematology, 82, 1136-1139.
72. Porter, J.B., Abeysinghe, R.D., Marshall, L., Hider, R.C. & Singh, S. (1996) Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. Blood, 88, 705-713.
73. Porter, J.B., Walter, P.B., Neumayr, L.D., Evans, P., Bansal, S., Garbowski, M., Weyhmiller, M.G., Harmatz, P.R., Wood, J.C., Miller, J.L., Byrnes, C., Weiss, G., Seifert, M., Grosse, R., Grabowski, D., Schmidt, A., Fischer, R., Nielsen, P., Niemeyer, C. & Vichinsky, E. (2014) Mechanisms of plasma non-transferrin bound iron generation: insights from comparing transfused diamond blackfan anaemia with sickle cell and thalassaemia patients. British Journal of Hematology, 167, 692-696.
74. Puliyel, M., Sposto, R., Berdoukas, V.A., Hofstra, T.C., Nord, A., Carson, S., Wood, J. & Coates, T.D. (2014) Ferritin trends do not predict changes in total body iron in patients with transfusional iron overload. American Journal of Hematology, 89, 391-394.
75. Restaino, G., Meloni, A., Positano, V., Missere, M., Rossi, G., Calandriello, L., Keilberg, P., Mattioni, O., Maggio, A., Lombardi, M., Sallustio, G. & Pepe, A. (2011) Regional and global pancreatic T*2 MRI for iron overload assessment in a large cohort of healthy subjects: normal values and correlation with age and gender. Magnetic Resonance in Medicine, 65, 764-769.
76. Roghi, A., Cappellini, M.D., Wood, J.C., Musallam, K.M., Patrizia, P., Fasulo, M.R., Cesaretti, C. & Taher, A.T. (2010) Absence of cardiac siderosis despite hepatic iron overload in Italian patients with thalassemia intermedia: an MRI T2* study. Annals of Hematology, 89, 585-589.
77. Rose, C., Vandevenne, P., Bourgeois, E., Cambier, N. & Ernst, O. (2006) Liver iron content assessment by routine and simple magnetic resonance imaging procedure in highly transfused patients. European Journal of Hematology, 77, 145-149.
78. Ruccione, K.S., Mudambi, K., Sposto, R., Fridey, J., Ghazarossian, S. & Freyer, D.R. (2012) Association of projected transfusional iron burden with treatment intensity in childhood cancer survivors. Pediatric Blood & Cancer, 59, 697-702.
79. Sado, D.M., Maestrini, V., Piechnik, S.K., Banypersad, S.M., White, S.K., Flett, A.S., Robson, M.D., Neubauer, S., Ariti, C., Arai, A., Kellman, P., Yamamura, J., Schoennagel, B.P., Shah, F., Davis, B., Trompeter, S., Walker, M., Porter, J. & Moon, J.C. (2014) Noncontrast myocardial T mapping using cardiovascular magnetic resonance for iron overload. Journal of Magnetic Resonance Imaging, doi: 10.1002/jmri.24727.
80. Sohn, Y.S., Ghoti, H., Breuer, W., Rachmilewitz, E., Attar, S., Weiss, G. & Cabantchik, Z.I. (2012) The role of endocytic pathways in cellular uptake of plasma non-transferrin iron. Haematologica, 97, 670-678.
81. St Pierre, T.G., Clark, P.R., Chua-anusorn, W., Fleming, A.J., Jeffrey, G.P., Olynyk, J.K., Pootrakul, P., Robins, E. & Lindeman, R. (2005) Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood, 105, 855-861.
82. St Pierre, T.G., El-Beshlawy, A., Elalfy, M., Al Jefri, A., Al Zir, K., Daar, S., Habr, D., Kriemler-Krahn, U. & Taher, A. (2014) Multicenter validation of spin-density projection-assisted R2-MRI for the noninvasive measurement of liver iron concentration. Magnetic Resonance in Medicine, 71, 2215-2223.
83. Stark, D.D., Bass, N.M., Moss, A.A., Bacon, B.R., McKerrow, J.H., Cann, C.E., Brito, A. & Goldberg, H.I. (1983) Nuclear magnetic resonance imaging of experimentally induced liver disease. Radiology, 148, 743-751.
84. Storey, P., Thompson, A.A., Carqueville, C.L., Wood, J.C., de Freitas, R.A. & Rigsby, C.K. (2007) R2* imaging of transfusional iron burden at 3T and comparison with 1.5T. Journal of Magnetic Resonance Imaging, 25, 540-547.
85. Taher, A.T., Porter, J.B., Viprakasit, V., Kattamis, A., Chuncharunee, S., Sutcharitchan, P., Siritanaratkul, N., Origa, R., Karakas, Z., Habr, D., Zhu, Z. & Cappellini, M.D. (2015) Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia. British Journal of Hematology, 168, 284-90.
86. Tanner, M.A., He, T., Westwood, M.A., Firmin, D.N. & Pennell, D.J. (2006) Multi-center validation of the transferability of the magnetic resonance T2* technique for the quantification of tissue iron. Haematologica, 91, 1388-1391.
87. Tanner, M.A., Galanello, R., Dessi, C., Smith, G.C., Westwood, M.A., Agus, A., Roughton, M., Assomull, R., Nair, S.V., Walker, J.M. & Pennell, D.J. (2007) A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation, 115, 1876-1884.
88. Tanner, M.A., Galanello, R., Dessi, C., Smith, G.C., Westwood, M.A., Agus, A., Pibiri, M., Nair, S.V., Walker, J.M. & Pennell, D.J. (2008) Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. Journal of Cardiovascular Magnetic Resonance, 10, 12.
89. Tsai, Y.S., Chen, J.S., Wang, C.K., Lu, C.H., Cheng, C.N., Kuo, C.S., Liu, Y.S. & Tsai, H.M. (2014) Quantitative assessment of iron in heart and liver phantoms using dual-energy computed tomography. Experimental Therapeutics in Medicine, 8, 907-912.
90. Villeneuve, J.P., Bilodeau, M., Lepage, R., Cote, J. & Lefebvre, M. (1996) Variability in hepatic iron concentration measurement from needle-biopsy specimens. Journal of Hepatology, 25, 172-177.
91. Wali, Y.A., Taqi, A. & Deghaidi, A. (2004) Study of intermittent intravenous deferrioxamine high-dose therapy in heavily iron-loaded children with beta-thalassemia major poorly compliant to subcutaneous injections. Pediatric Hematology Oncology, 21, 453-460.
92. Walter, P.B., Fung, E.B., Killilea, D.W., Jiang, Q., Hudes, M., Madden, J., Porter, J., Evans, P., Vichinsky, E. & Harmatz, P. (2006) Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease. British Journal of Hematology, 135, 254-263.
93. Westwood, M.A., Anderson, L.J., Firmin, D.N., Gatehouse, P.D., Lorenz, C.H., Wonke, B. & Pennell, D.J. (2003) Interscanner reproducibility of cardiovascular magnetic resonance T2* measurements of tissue iron in thalassemia. Journal of Magnetic Resonance Imaging, 18, 616-620.
94. Westwood, M.A., Anderson, L.J., Maceira, A.M., Shah, F.T., Prescott, E., Porter, J.B., Wonke, B., Walker, J.M. & Pennell, D.J. (2007) Normalized left ventricular volumes and function in thalassemia major patients with normal myocardial iron. Journal of Magnetic Resonance Imaging, 25, 1147-1151.
95. Wood, J.C. (2008) Cardiac iron across different transfusion-dependent diseases. Blood Reviews, 22, S14-S21.
96. Wood, J.C. (2009) History and current impact of cardiac magnetic resonance imaging on the management of iron overload. Circulation, 120, 1937-1939.
97. Wood, J.C. (2014) Use of magnetic resonance imaging to monitor iron overload. Hematology Oncology Clinics of North America, 28, 747-764, vii.
98. Wood, J.C., Enriquez, C., Ghugre, N., Tyzka, J.M., Carson, S., Nelson, M.D. & Coates, T.D. (2005a) MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood, 106, 1460-1465.
99. Wood, J.C., Enriquez, C., Ghugre, N., Otto-Duessel, M., Aguilar, M., Nelson, M.D., Moats, R. & Coates, T.D. (2005b) Physiology and pathophysiology of iron cardiomyopathy in thalassemia. Annals of the New York Academy of Sciences, 1054, 386-395.
100. Wood, J.C., Otto-Duessel, M., Aguilar, M., Nick, H., Nelson, M.D., Coates, T.D., Pollack, H. & Moats, R. (2005c) Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy. Circulation, 112, 535-543.
101. Wood, J.C., Kang, B.P., Thompson, A., Giardina, P., Harmatz, P., Glynos, T., Paley, C. & Coates, T.D. (2010) The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood, 116, 537-543.
102. Wood, J.C., Glynos, T., Thompson, A., Giardina, P., Harmatz, P., Kang, B.P., Paley, C. & Coates, T.D. (2011a) Relationship between labile plasma iron, liver iron concentration and cardiac response in a deferasirox monotherapy trial. Haematologica, 96, 1055-1058.
103. Wood, J.C., Mo, A., Gera, A., Koh, M., Coates, T. & Gilsanz, V. (2011b) Quantitative computed tomography assessment of transfusional iron overload. British Journal of Hematology, 153, 780-785.
104. Wood, J.C., Zhang, P., Rienhoff, H., Abi-Saab, W. & Neufeld, E. (2013) Liver MRI is better than biopsy for assessing total boday iron balance: validation by simulation. Blood, 122, 958.
105. Wood, J.C., Zhang, P., Rienhoff, H., Abi-Saab, W. & Neufeld, E. (2014) R2 and R2* are equally effective in evaluating chronic response to iron chelation. American Journal of Hematology, 89, 505-508.
106. Zanninelli, G., Breuer, W. & Cabantchik, Z.I. (2009) Daily labile plasma iron as an indicator of chelator activity in thalassaemia major patients. British Journal of Hematology, 147, 744-751.